Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Gamma-Cyclodextrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.95 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.74 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.74 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betadex SCHEMBL692932 | 1.00 | ALDH1A1 (0.95) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL11030738 | 1.00 | ALDH1A1 (0.95) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL28176234 | 1.00 | ALDH1A1 (0.95) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL2432145 | 1.00 | ALDH1A1 (0.95) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL7195429 | 0.98 | ALDH1A1 (0.91) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Gamma-Cyclodextrin SCHEMBL25455463 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL23188277 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Gamma-Cyclodextrin SCHEMBL25455531 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23188251 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Gamma-Cyclodextrin SCHEMBL20533920 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119452101-A | Compositions and methods for nucleic acid sequencing | 因美纳公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119095982-A | Palladium catalyst compositions and methods for sequencing-by-synthesis | 伊路米纳有限公司 | 2024-12-06 | — | — | CN | claimed |
| US-8435966-B2 | Associations of xanthogenates and cyclodextrins, and their use | BIOSPHINGS AG (DE) | 2013-05-07 | — | — | US | claimed |
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2010-09-23 | — | — | US | claimed |
| US-6284269-B1 | Pharmaceutical compositions of meloxicam with improved solubility and bioavailability | HEXAL AG (DE) | 2001-09-04 | — | — | US | claimed |
| EP-1007049-A1 | NEW PHARMACEUTICAL COMPOSITIONS OF MELOXICAM WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | Hexal AG (DE) | 2000-06-14 | — | — | EP | claimed |
| WO-1999009988-A1 | NEW PHARMACEUTICAL COMPOSITIONS OF MELOXICAM WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | HEXAL AG (DE) | 1999-03-04 | — | — | WO | claimed |
| CN-119095982-A | Palladium catalyst compositions and methods for sequencing-by-synthesis | 伊路米纳有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-112961124-B | Method for treating sewage by using microbial preparation | 杭州楠大环保科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-112961124-A | Method for treating sewage by using microbial preparation | 杭州楠大环保科技有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-112585457-A | Systems, devices, and methods for gas sensing | 麻省理工学院 | 2021-03-30 | — | — | CN | disclosed |
| CN-107626337-A | A kind of loaded Ag/g C3N4The preparation method of aerogel microball | 东北林业大学 | 2018-01-26 | — | — | CN | disclosed |
| US-8435966-B2 | Associations of xanthogenates and cyclodextrins, and their use | BIOSPHINGS AG (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010086129-A1 | INCLUSION COMPLEX COMPRISING CINACALCET AND CYCLODEXTRIN | RATHIOPHARM GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
| CN-1671421-A | Inclusion complexes of rosiglitazone | GLAXO GROUP LTD (GB) | 2005-09-21 | — | — | CN | disclosed |
| US-6284269-B1 | Pharmaceutical compositions of meloxicam with improved solubility and bioavailability | HEXAL AG (DE) | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | HLA-DRB1, CXCR3, ANTXR2 | HDAC3 2096/4885HDAC1 1496/4885HDAC2 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.